🕒 Last update: loading…

Stock Summit Therapeutics Inc. SMMT

Summit Therapeutics Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ✅ Price trend passed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 39.13%

Price change 2019 → 2020: 193.75%

Price change 2020 → 2021: -42.77%

Price change 2021 → 2022: 57.99%

Price change 2022 → 2023: -38.59%

Price change 2023 → 2024: 583.91%

Price change 2024 → 2025: -2.02%

Price change 2025 → 2026: -4.57%

Price change 2026 (year to date): -4.74%

Financial growth

Revenue CAGR (8 years): -100.00%

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.03

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -14.96

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 36.73% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Summit Therapeutics Inc.–0.03–🔒
Tempus AI, Inc.–2.70+65.4 %–
bioMérieux S.A.23.50.11+7.6 %★ 4/5
Ipsen S.A.25.60.20+7.9 %–
Bio-Rad Laboratories, Inc.41.10.20+2.0 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Summit Therapeutics Inc. over the latest fiscal years.

Revenue
704,295 USD
fiscal year 2022
Net income
-78.8 m USD
fiscal year 2022
Net margin
-11,185.9 %
fiscal year 2022
Average annual growth
-50.3 %
Revenue growth over 5 years
Average annual growth
-15.5 %
Revenue growth over 10 years
Market cap
11.3 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
201723.1 m-37.7 m-163.1 %n/a
201874.5 m13.0 m17.5 %+222.5 %
2019808,413-31.6 m-3,903.4 %-98.9 %
2020860,000-52.7 m-6,127.6 %+6.4 %
20211.8 m-88.6 m-4,897.8 %+110.3 %
2022704,295-78.8 m-11,185.9 %-61.1 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Summit Therapeutics Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
21.15
safe zone (above 2.99)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
0.16 x
low debt
Fiscal year20212022202320242025
Cash and investments53.2 m284 m147 m330 m713 m
Total Debt2.1 m423 m84.0 m5.8 m20.9 m
Net Debt-51.2 m139 m27.4 m-78.0 m-204 m
Equity61.7 m103 m61.5 m311 m659 m
Total assets84.0 m541 m161 m348 m751 m
Operating cash flow-53.8 m-33.9 m-60.7 m-114 m-323 m
Investments (capex)226,830508,681101,293111,073657,000
Free cash-flow-54.0 m-34.4 m-60.8 m-114 m-324 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-9.88 x
Price / book value14.94 x
Return on Equity (ROE)-138.8 %
Return on Invested Capital (ROIC)-145.8 %
Net margin0.0 %
Debt / equity0.04 x
Current ratio5.99 x
Free cash-flow yield-6.2 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Summit Therapeutics Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Summit Therapeutics Inc.11.3 bnn/a0.0 %
Spero Therapeutics, Inc. SPRO58.3 m4.214.4 %
Acurx Pharmaceuticals, Inc. ACXP5.8 mn/a0.0 %
ImmunityBio, Inc. IBRX6.4 bnn/a-310.2 %
Palisade Bio, Inc. PALI201 mn/a0.0 %
Seres Therapeutics, Inc. MCRB14.3 mn/a721.9 %
Traws Pharma, Inc. TRAW3.9 mn/a328.7 %
Enanta Pharmaceuticals, Inc. ENTA320 mn/a-125.4 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Summit Therapeutics Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
23 analysts
Average price target
33.13 USD
from 20.00 USD to 41.00 USD, 15 targets over 12 months
Gap with the share price
+134.1 %
price 14.15 USD on 13/11/2026

Breakdown of ratings

strong buy 0buy 15hold 8sell 0strong sell 0

Average target over the last 3 months: 28.70 USD (7 targets).

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
20263.7 m-794 m-1.16 (-1.42 / -1.02)n/a9
202759.5 m-947 m-1.13 (-1.36 / -0.95)n/a8
2028581 m-677 m-0.69 (-1.18 / 0.22)n/a7

Amounts in GBP, the reporting currency.

Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
01/10/2026BarclaysEqual WeightEqual Weight
29/09/2026CitigroupBuyBuy
23/09/2026HC Wainwright & Co.NeutralNeutral
09/09/2026JefferiesHoldBuy
26/08/2026HC Wainwright & Co.NeutralNeutral

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Summit Therapeutics Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
04/11/2026-0.26-0.28n/a
23/07/2026-0.28-0.27n/a
30/04/2026-0.24-0.33n/a
23/02/2026-0.29-0.10n/a
20/10/2025-0.31-0.18n/a
11/08/2025-0.76-0.09n/a

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Summit Therapeutics Inc.

Free float
13.8 %
share of freely traded shares
Large funds tracked
23
hold the stock as of 2026Q2

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
State Street19.1 m278 m0.0 %+171.4 %2026Q2
Vanguard Group11.2 m195 m0.0 %-1.8 %2025Q4
Fidelity10.0 m146 m0.0 %-7.5 %2026Q2
BlackRock9.5 m139 m0.0 %-1.3 %2026Q2
Goldman Sachs4.5 m65.8 m0.0 %+1,352.5 %2026Q2
T. Rowe Price3.9 m56.7 m0.0 %-53.0 %2026Q2
Point72 Asset Management3.7 m53.9 m0.1 %+371.5 %2026Q2
Citadel Advisors3.5 m50.3 m0.0 %+681.3 %2026Q2

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 05/03/2015
ISIN code
US86627T1088
Workforce
159
full-time employees
Chief executive
Robert W. Duggan
Next earnings
22/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Summit Therapeutics Inc.

What is the Summit Therapeutics Inc. share price?

Latest recorded price: 14.15 USD on 13/11/2026, for a market cap of 11.3 bn USD.

What is the revenue of Summit Therapeutics Inc.?

704,295 USD for fiscal year 2022, with net income of -78.8 m USD (net margin -11,185.9 %).

When does Summit Therapeutics Inc. report its next earnings?

The next release is expected on 22/02/2027. EPS expected by analysts: -0.34.

What do analysts say about Summit Therapeutics Inc.?

Out of 23 analysts: 15 buy or strong buy, 8 hold, 0 sell or strong sell. Average price target: 33.13 USD, i.e. +134.1 % from the share price.

Is Summit Therapeutics Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US86627T1088).

How many employees does Summit Therapeutics Inc. have?

159 full-time employees according to the latest published profile.

Who runs Summit Therapeutics Inc.?

Robert W. Duggan is the company's chief executive.

Which large funds own Summit Therapeutics Inc.?

As of 2026Q2, among the large funds tracked: State Street, Vanguard Group, Fidelity, BlackRock, Goldman Sachs.

07

Similar stocks